Lupin Ltd., India’s second-largest drugmaker by market value, and Cipla Ltd. are among companies that bid for UCB SA’s U.S. generic-drug business, people with knowledge of the matter said.
The Indian companies submitted first-round offers for UCB’s Kremers Urban Pharmaceuticals Inc. unit in late April, the people said, asking not to be identified because the process is private. The business could be valued at about $1 billion, four of the people said.
Help employers find you! Check out all the jobs and post your resume.
